BridgeBio to Discuss Phase 2 Infigratinib Results for Achondroplasia on June 4, 2024

PALO ALTO, Calif., June 03, 2024, -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company dedicated to genetic diseases, has scheduled a call for June 4, 2024, at 8:00 am ET. The purpose of the call is to present outcomes from Month 12 and Month 18 for Cohort 5 in the PROPEL 2 trial, which is a Phase 2 study assessing the oral therapy infigratinib for children with achondroplasia.

The call will feature BridgeBio’s management team and Ravi Savarirayan, M.D., Ph.D., from Murdoch Children’s Research Institute, Melbourne, Australia, who is the global lead investigator for PROPEL 2. Interested individuals can participate in the live webcast by visiting the “Events” page in the Investors section of BridgeBio’s website. A replay will be accessible on the site for 90 days post-event.

BridgeBio Pharma, Inc., established in 2015, focuses on discovering, developing, and delivering transformative treatments for genetic diseases. The company’s development pipeline spans from initial scientific research to advanced clinical trials. BridgeBio’s team comprises seasoned drug discoverers, developers, and innovators committed to leveraging genetic medicine advancements to expedite patient care.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!